Skip to main content
. 2017 Dec 18;15(3):3287–3294. doi: 10.3892/ol.2017.7633

Figure 4.

Figure 4.

DACT2 represses the expression of β-catenin target genes in breast cancer cells. (A) The overexpression of DACT2 or 5-Aza treatment resulted in the decrease of β-catenin in MDA-MB-468 cells. (B) The knockdown of DACT2 resulted in the elevated expression of β-catenin. (C) The knockdown of DACT2 in MDA-MB-231 cells elevated the mRNA level of cyclin D1 and MMP7. (D) The overexpression of DACT2 attenuated the mRNA level of cyclin D1 and MMP7. (E) The overexpression of DACT2 attenuated β-catenin reporter (wide) luciferase activity. (F) The knockdown of DACT2 elevated β-catenin reporter (wide) luciferase activity. (G) The overexpression of DACT2 did not affect β-catenin reporter (mutant) luciferase activity. (H) The knockdown of DACT2 did not affect β-catenin reporter (mutant) luciferase activity. DACT2, dishevelled-associated antagonist of β-catenin homolog 2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MMP7, matrix metalloproteinase 7; siRNA, small interfering RNA; NC, negative control.